Created in 2021, Palade BioTech is a South Korean firm committed to finding innovative solutions for some of the world’s biggest medical challenges. We focus on developing new, innovative technologies using synthetic biology and click synthetic chemistry tools to provide solutions.
We focus on four key areas:
Our mission is to create innovative treatments and solutions for the toughest biological challenges where no viable treatments currently exist. The Palade BioTech team is led by Bong-Kwan Han, a globally recognized pioneer in the field of medical synthetic biology, and an additional three members dedicated to finding solutions to some of the most pressing healthcare issues facing society.
Our mission is to transform outcomes for patients with life-threatening diseases who currently have no effective treatment options. We are committed to delivering first-in-class, biology-driven therapeutics that overcome resistance mechanisms in both cancer and infectious diseases, addressing the urgent unmet needs of patients left behind by existing therapies.
Through scientific innovation, strategic partnerships, and rapid translational development, we aim to bring hope and survival to those fighting drug-resistant tumors and incurable viral infections such as HBV and Zika virus.
We envision becoming a global biotech leader in resistance-targeted therapeutics, developing curative solutions for the hardest-to-treat cancers and untreatable viral diseases. Our integrated pipeline leverages our proprietary platforms to deliver breakthrough treatments across two high-impact domains of drug-resistant cancers and incurable viral infections .
By focusing on diseases with high mortality, no effective treatments, and global impact, we aim to build a differentiated, resilient, and purpose-driven biotech company that creates lasting value for patients, partners, and shareholders.
We are building a differentiated biotech company with two ambitious and synergistic goals aimed at transforming care for patients with the fewest options:
Adipiscing diam donec adipiscing tristique risus. Fames ac turpis egestas sed tempus urna et. Fringilla ut morbi tincidunt augue interdum velit euismod. Viverra vitae congue eu consequat ac felis. Nisl nunc mi ipsum faucibus vitae aliquet nec. Pharetra magna ac placerat vestibulum lectus mauris ultrices eros. Imperdiet nulla malesuada pellentesque elit eget gravida cum sociis. In hac habitasse platea dictumst quisque sagittis. Ornare arcu dui vivamus arcu felis bibendum ut tristique. Etiam sit amet nisl purus. Accumsan sit amet nulla facilisi morbi tempus. Ut placerat orci nulla pellentesque.
“Richard” Bong-Kwan Han, Founder and CEO
Bong-Kwan Han, also known as Richard Han, launched Palade BioTech in late 2021 to create innovative solutions to some of the most pressing medical challenges today. He is a scientist, researcher, engineer, and entrepreneur. He earned his initial Bachelor of Science and M.S. from the prestigious Seoul National University and Korea Advanced Institute of Science & Technology, KAIST, respectively, before gaining his Ph. D. from Texas A&M, CS where he was called “phenom” by professors and he also received the John Mack Prescott Student of the Year Award. Bong-Kwan was also an investigator at KAIST.”
He continued his education at the Scripps Research Institute and Howard Hughes Medical Institute. Bong-Kwan worked as a researcher in Cell and Molecular Medicine at the Weill Inst. for Cell and Molecular Biology and the South Korean Mogam Biotechnology Research Institute. He was also an investigator at the KAIST, the Intelligent Synthetic Biology Center in South Korea.
Dr. Scott Emr_
ESCRT discoverer,
1st experimental discoverer of
Dr. Blobel’s signal sequence theory,
my scientific father, collaborator,
& coauthor
Dr. Tony Hunter_
RTK discoverer,
my collaborator
& coauthor
Drs. G. Palade, S. Emr, R. Schekman, G. Blobel, T. Hunter, R. Tsien et al.
(Palade, Tsien, Schekman, Blobel are Nobel Laureates)
We are a purpose-driven biotech company dedicated to transforming the lives of patients with life-threatening diseases who have no effective treatment options. By focusing where others cannot, we aim to build a resilient, trusted company that delivers lasting impact to patients, partners, and the global healthcare community.
With a bold vision to become a global leader in resistance-targeted therapeutics, we are pioneering curative solutions for drug-resistant, immunotherapy-refractory cancers and incurable viral threats, the areas of highest mortality and unmet need.